HRP20170250T1 - Dvofazni pripravak lipidnih vezikula i postupak za liječenje cervikalne displazije intravaginalnom isporukom - Google Patents

Dvofazni pripravak lipidnih vezikula i postupak za liječenje cervikalne displazije intravaginalnom isporukom

Info

Publication number
HRP20170250T1
HRP20170250T1 HRP20170250TT HRP20170250T HRP20170250T1 HR P20170250 T1 HRP20170250 T1 HR P20170250T1 HR P20170250T T HRP20170250T T HR P20170250TT HR P20170250 T HRP20170250 T HR P20170250T HR P20170250 T1 HRP20170250 T1 HR P20170250T1
Authority
HR
Croatia
Prior art keywords
vescules
displasion
cervical
lipid
procedure
Prior art date
Application number
HRP20170250TT
Other languages
English (en)
Croatian (hr)
Inventor
Marianna Foldvari
Praveen Kumar
John M. Docherty
Original Assignee
Helix Biopharma Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helix Biopharma Corp. filed Critical Helix Biopharma Corp.
Publication of HRP20170250T1 publication Critical patent/HRP20170250T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20170250TT 2007-03-30 2008-03-27 Dvofazni pripravak lipidnih vezikula i postupak za liječenje cervikalne displazije intravaginalnom isporukom HRP20170250T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90932407P 2007-03-30 2007-03-30
EP08733666.5A EP2134353B1 (en) 2007-03-30 2008-03-27 Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery
PCT/CA2008/000563 WO2008119160A1 (en) 2007-03-30 2008-03-27 Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery

Publications (1)

Publication Number Publication Date
HRP20170250T1 true HRP20170250T1 (hr) 2017-04-07

Family

ID=39807744

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170250TT HRP20170250T1 (hr) 2007-03-30 2008-03-27 Dvofazni pripravak lipidnih vezikula i postupak za liječenje cervikalne displazije intravaginalnom isporukom

Country Status (18)

Country Link
US (3) US8945529B2 (enExample)
EP (1) EP2134353B1 (enExample)
JP (1) JP5587762B2 (enExample)
KR (1) KR20090130081A (enExample)
AU (1) AU2008234364B2 (enExample)
CA (1) CA2681565C (enExample)
CY (1) CY1118794T1 (enExample)
DK (1) DK2134353T3 (enExample)
ES (1) ES2617063T3 (enExample)
HR (1) HRP20170250T1 (enExample)
HU (1) HUE033256T2 (enExample)
LT (1) LT2134353T (enExample)
MX (1) MX2009010405A (enExample)
PL (1) PL2134353T3 (enExample)
PT (1) PT2134353T (enExample)
SI (1) SI2134353T1 (enExample)
TW (1) TWI440477B (enExample)
WO (1) WO2008119160A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008900B1 (fr) * 2013-07-25 2018-03-30 Centre Nat Rech Scient Nanoparticules lipidiques multicompartimentees
US8986732B2 (en) * 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US10159646B2 (en) * 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US20150147382A1 (en) * 2013-09-23 2015-05-28 Exir Nano Sina Company Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same
US11485972B2 (en) 2017-05-18 2022-11-01 Modernatx, Inc. Modified messenger RNA comprising functional RNA elements
US20180360757A1 (en) * 2017-05-26 2018-12-20 Altum Pharmaceuticals Inc. Biphasix cannabinoid delivery
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
CA3079428A1 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
MX2021003015A (es) 2018-09-13 2021-07-15 Modernatx Inc Polinucleotidos que codifican glucosa-6-fosfatasa para el tratamiento de la glucogenosis.
JP2022500444A (ja) 2018-09-14 2022-01-04 モダーナティエックス・インコーポレイテッドModernaTX, Inc. クリグラー−ナジャー症候群の治療のためのウリジン二リン酸グリコシルトランスフェラーゼ１ファミリー、ポリペプチドａ１をコードするポリヌクレオチド
EP4034087A4 (en) 2019-09-23 2023-10-25 DDS Research Inc. LIPID VESICLE COMPOSITIONS USING PENETRATION ENHANCING AGENTS
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
US20240207374A1 (en) 2021-03-24 2024-06-27 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
WO2022204305A2 (en) 2021-03-24 2022-09-29 Glo Pharma, Inc. Peptides and methods for reducing skin pigmentation
US20240216288A1 (en) 2021-03-24 2024-07-04 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
WO2022271776A1 (en) 2021-06-22 2022-12-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
KR20240102989A (ko) * 2021-11-04 2024-07-03 글로 파마, 인크. 화장품 적용을 위한 방법 및 조성물
WO2024026254A1 (en) 2022-07-26 2024-02-01 Modernatx, Inc. Engineered polynucleotides for temporal control of expression
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
DE69425750T2 (de) * 1993-07-28 2001-04-26 Pharmaderm Laboratories Ltd., Saskatoon Zweiphasige multilamellare lipidvesikel
IN184589B (enExample) * 1996-10-16 2000-09-09 Alza Corp
US5993852A (en) * 1997-08-29 1999-11-30 Pharmaderm Laboratories Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
US6656499B1 (en) * 1999-11-12 2003-12-02 Pharmaderm Laboratories, Ltd. Composition for transdermal and dermal administration of interferon-α
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
EP1576952A1 (en) * 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile

Also Published As

Publication number Publication date
WO2008119160A1 (en) 2008-10-09
TW200846030A (en) 2008-12-01
SI2134353T1 (sl) 2017-03-31
EP2134353A1 (en) 2009-12-23
CY1118794T1 (el) 2017-07-12
US8945529B2 (en) 2015-02-03
KR20090130081A (ko) 2009-12-17
EP2134353A4 (en) 2013-08-07
US20100196453A1 (en) 2010-08-05
CA2681565A1 (en) 2008-10-09
HUE033256T2 (hu) 2017-11-28
PL2134353T3 (pl) 2017-06-30
AU2008234364B2 (en) 2013-10-17
LT2134353T (lt) 2017-03-27
CA2681565C (en) 2016-10-25
AU2008234364A1 (en) 2008-10-09
MX2009010405A (es) 2010-02-03
JP5587762B2 (ja) 2014-09-10
TWI440477B (zh) 2014-06-11
ES2617063T3 (es) 2017-06-15
EP2134353B1 (en) 2016-11-16
DK2134353T3 (en) 2017-02-20
US20130216610A1 (en) 2013-08-22
JP2010522698A (ja) 2010-07-08
PT2134353T (pt) 2017-02-15
US20130224283A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
HRP20170250T1 (hr) Dvofazni pripravak lipidnih vezikula i postupak za liječenje cervikalne displazije intravaginalnom isporukom
IL216876A (en) Cationic lipid, lipid formulations comprising same and use thereof in the preparation of therapeutic agents for delivering to cells
PL2442814T3 (pl) Bifidobacteria do leczenia cukrzycy i pokrewnych chorób
HUE069458T2 (hu) Terápiás hatóanyagok bejuttatására szolgáló új lipidek és készítmények
HUS1600048I1 (hu) Készítmény Fabry-kór kezelésére
HRP20170926T1 (hr) Antisens kompozicije i postupci za pripremu i uporabu istih
PL2037902T3 (pl) Zastosowanie kanabidiolu w użyciu w leczeniu bólu neuropatycznego
IL217540A (en) Oral composition for use in oral disinfection or in treating an oral disease
BRPI1011876A2 (pt) "composição farmacêutica estável e métodos de uso da mesma"
HRP20170929T1 (hr) Farmaceutski pripravci i odgovarajući postupci za isporuku
PT2426148E (pt) Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
BR112012004148A2 (pt) "dispositivo médico para colocação em um lúmen e método de fabricação do mesmo"
EP2147437A4 (en) SEEDING REPLICATION
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
IL202614A0 (en) Intravaginal drug delivery devices for the delivery of macromolecules and water soluble drugs
DK2227243T3 (da) Farmaceutisk sammensætning til behandling af obesitet relaterede sygdomme, omfattende et insulinotropisk peptidkonjugat
PT2376537T (pt) Anticorpos humanos contra fator tecidual humano
EP2790736A4 (en) IN VIVO ADMINISTRATION OF OLIGONUCLEOTIDES
BR112012014962A2 (pt) métodos e composições para formulações líquidas e estáveis de fármacos
DK2432456T3 (da) Faste farmaceutiske sammensætninger og fremgangsmåder til fremstilling deraf
ZA200904756B (en) Methods of vaccine administration
IL209336B (en) Compositions for treating hyperproliferative diseases and uses thereof
BRPI1013249A2 (pt) "forma cristalina vi da agomelatina, preparação e uso da mesma."
DK2448940T3 (da) Derivater af 6,7,8,9 tetrahydro-pyrimido{1,2-a}pyrimidin-4-on, fremstilling og farmaceutisk anvendelse heraf
BR112012007642A2 (pt) "composições líquidas precursoras para tratamento de difusões orais com ph-dependente de liberação sustentada e respectivo uso"